Health-related quality of life in French people living with HIV in 2003: Results from the national ANRS-EN12-VESPA study

AIDS

Volumn 21, Issue SUPPL. 1, 2007, Pages

  Préau, Marie ^a,b,c   Marcellin, Fabienne ^a,b   Carrieri, Marie Patrizia ^a,b   Lert, France ^a   Obadia, Yolande ^a,b   Spire, Bruno ^a,b  

^a INSERM   (France)

^b OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Co infection; Disclosure; Discrimination; Quality of life

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT;

ADULT; AGE DISTRIBUTION; ANXIETY; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; FEMALE; FOLLOW UP; FRANCE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEX RATIO; SHORT FORM 36; STATISTICAL ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE TO HEALTH; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH STATUS INDICATORS; HIV INFECTIONS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; SELECTION BIAS;

EID: 33845775798     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000255081.24105.d7     Document Type: Article

References (34)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363-367.
3. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W, Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999; 25:383-392.
4. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23:236-245.
5. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
6. Carrieri MP, Spire B, Duran S, Katlama C, Peyramond D, Francois C, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32:38-47.
7. Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Braitstein P, et al. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004; 36:743-749.
8. Sabin CA, Walker AS, Dunn D. HIV/HCV coinfection, HAART, and liver-related mortality. Lancet 2004; 364:757-758; author reply 758.
9. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
10. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212.
11. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30:1299-1301.
12. Dray-Spira R, Spire B, Heard I, Lert F, and the VESPA Group. Heterogeneous response to HAART across a diverse population of HIV-infected individuals - results from the ANRS-EN12-VESPA Study. AIDS 2006; 21 (Suppl. 1):S5-S12.
13. Leplege A, Ecosse E, Verdier A, Perneger TV. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51:1013-1023.
14. Peretti-Watel P, Spire B, Lert F, Obadia Y, and the VESPA Group. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend 2005; 82:571-579.
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370.
16. Barczak P, Kane N, Andrews S, Congdon AM, Clay JC, Betts T. Patterns of psychiatric morbidity in a genito-urinary clinic. A validation of the Hospital Anxiety Depression scale (HAD). Br J Psychiatry 1988; 152:698-700.
17. Anderberg MR. Cluster analysis for applications. Academic Press New York and London; 1973.
18. Heckman J. Sample selection bias as a specification error. Econometrica 1979; 47:153-161.
19. Alonso J, Ferrer M, Gandek B, Ware JE Jr, Aaronson NK, Mosconi P, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 2004; 13:283-298.
20. Hopman WM, Berger C, Joseph L, Towheed T, VandenKerkhof E, Anastassiades T, et al. The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population. Qual Life Res 2006; 15:527-536.
21. Lindholm E, Brevinge H, Bergh CH, Korner U, Lundholm K. Relationships between self-reported health related quality of life and measures of standardized exercise capacity and metabolic efficiency in a middle-aged and aged healthy population. Qual Life Res 2003; 12:575-582.
22. Blalock AC, McDaniel JS, Farber EW. Effect of employment on quality of life and psychological functioning in patients with HIV/AIDS. Psychosomatics 2002; 43:400-404.
23. Preau M, Leport C, Salmon-Ceron D, Carrieri P, Portier H, Chene G, et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care 2004; 16:649-661.
24. Chandra PS, Deepthivarma S, Jairam KR, Thomas T. Relationship of psychological morbidity and quality of life to illness-related disclosure among HIV-infected persons. J Psychosom Res 2003; 54:199-203.
25. Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med 2003; 57:13-24.
26. te Vaarwerk MJ, Gaal EA. Psychological distress and quality of life in drug-using and non-drug-using HIV-infected women. Eur J Pub Health 2001; 11:109-115.
27. Grella CE. Effects of gender and diagnosis on addiction history, treatment utilization, and psychosocial functioning among a dually-diagnosed sample in drug treatment. J Psychoactive Drugs 2003; 35 (Suppl. 1):169-179.
28. Trepanier LL, Rourke SB, Bayoumi AM, Halman MH, Krzyzanowski S, Power C. The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection. J Clin Exp Neuropsychol 2005; 27:1-15.
29. Bouhnik AD, Preau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10:53-61.
30. Jia H, Uphold CR, Wu S, Chen GJ, Duncan PW. Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. AIDS Patient Care STDS 2005; 19:395-405.
31. Kanwal F, Gralnek IM, Hays RD, Dulai GS, Spiegel BM, Bozzette S, Asch S. Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample. Am J Gastroenterol 2005; 100:1984-1994.
32. Braitstein P, Montessori V, Chan K, Montaner JS, Schechter MT, O'Shaughnessy MV, Hogg RS. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005; 17:505-515.
33. Blanch J, Rousaud A, Martinez E, De Lazzari E, Peri JM, Milinkovic A, et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr 2002; 31:404-407.
34. Nicholas PK, Kirksey KM, Corless IB, Kemppainen J. Lipodystrophy and quality of life in HIV: symptom management issues. Appl Nurs Res 2005; 18:55-58.